Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib in Relapsed or Refractory IDH1 Mutation-Positive AML
NCT07604064Phase 2Recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olutasidenib in acute myeloid leukemia (AML), sponsored by Kissei Pharmaceutical Co., Ltd.. Started Jun 2026; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07604064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604064.